替格瑞洛对经皮冠状动脉介入治疗术后急性冠脉综合征患者的疗效观察  

Observation on Efficacy of Ticagrelor on Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention

作　　者：崔勤[1] 周少名 杨加东 李辉[1] 钱青青 范杰 Cui Qin;Zhou Shaoming;Yang Jiadong;Li Hui;Qian Qingqing;Fan Jie(Department of Cardiovascular,Nantong Rich Hospital,Nantong 226010 China;Department of Cardiovascular,Haimen People蒺s Hospital,Haimen 226100 China)

机构地区：[1]南通瑞慈医院心内科,江苏南通226010 [2]海门市人民医院心内科,江苏海门226100

出　　处：《锦州医科大学学报》2018年第6期25-27,59,共4页Journal of Jinzhou Medical University

基　　金：2013年海门市社会发展科技项目;项目编号:2013sf11

摘　　要：目的探讨替格瑞洛对经皮冠状动脉介入治疗(PCI)术后急性冠脉综合征患者的疗效。方法选取2016年3月到2017年1月期间在我院接受治疗的ACS患者100例,根据乱数表法将患者分为对照组和观察组,两组均为50例。对照组采用阿司匹林肠溶片联合氯吡格雷进行治疗,观察组采用阿司匹林肠溶片联合替格瑞洛进行治疗。比较两组患者的血小板抑制率以及血清中的可溶性CD40配体(s CD40L)、超敏C反应蛋白(hs-CRP)、白介素-6 (IL-6)的水平,比较两组患者的主要心脏不良事件发生情况。结果治疗前两组患者的血小板抑制率比较差异无统计学意义(P>0.05),服药后2、24、48 h,观察组的血小板抑制率明显高于对照组(P<0.05);治疗前两组患者血清中的s CD40L、hs-CRP、IL-6水平比较差异无统计学意义(P>0.05),治疗后两组患者血清中的s CD40L、hs-CRP、IL-6水平均明显降低,且观察组血清中的s CD40L、hs-CRP、IL-6水平低于对照组(P<0.05);观察组的主要心脏不良事件发生率低于对照组(P<0.05)。结论替格瑞洛可有效提高PCI术后ACS患者的血小板抑制率,降低血清中的炎症因子水平和主要心脏不良事件发生率。Objective To investigate the efficacy of Ticagrelor on patients with acute coronary syndrome after percutaneous coro-nary intervention(PCI).Methods 100 ACS patients treated in our hospital from March 2016 to January 2017 were selected and ran-domly divided into control group and observation group with 50 cases in each group.The control group was treated with Aspirin Enteric-coated Tablets combined with clopidogrel,and the observation group was given Aspirin Enteric-coated Tablets combined with Ti-cagrelor.The rate of platelet inhibition and levels of soluble CD40 ligand(sCD40L),hypersensitive C reactive protein(hs-CRP)and interleukin-6(IL-6)in the serum of the two groups were compared,along with the major adverse cardiac events.Results There was no statistically significant difference in the platelet inhibition rate between the two groups before treatment(P>0.05).The platelet inhibition rate of the observation group was significantly higher than that of the control group 2,24,48 hours after taking the medicine(P<0.05).No statistically significant difference was shown in the levels of sCD40L,hs-CRP and IL-6 in the serum of the two groups before treatment(P>0.05).After treatment,the levels of sCD40L,hs-CRP and IL-6 in the serum of the two groups remark-ably decreased,and the three indicators of the observation group were lower than those of the control group(P<0.05).The incidence of major adverse cardiac events in the observation group was lower than that in the other group(P<0.05).Conclusion Ticagrelor can effectively improve the platelet inhibition rate in ACS patients after PCI,and reduce the levels of inflammatory factors and inci-dence of major adverse cardiac events.

关 键 词：急性冠脉综合征 经皮冠状动脉介入 替格瑞洛 疗效 

分 类 号：R541.4[医药卫生—心血管疾病]